Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: 2025 Eurostat Trade Data and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: 2025 Eurostat Trade Data and Economic Impact
Clinical Trials in the USA / NCT07782619
Recruiting Observational

Agreement of Two OCT Biometers: A Pilot Study

NCT07782619 · tracked via the Priya Life Science USA tracker
Sponsor
Alcon Research
Phase
Observational
Started
2026-08-17
Last updated
2026-09-02

Condition(s) studied

Anterior Segment of EyeAxial LengthBiometrics Measurement

Investigational drug(s) / intervention(s)

UNITY DXANTERION

UNITY DX: Investigational non-contact, non-invasive ophthalmic imaging and analysis device used for visualization of ocular structures and their optical properties

ANTERION: Commercially available non-contact, non-invasive ophthalmic imaging and analysis device used for visualization of ocular structures and their optical properties

Study summary

The purpose of this study is to compare the measurements obtained with two different biometers, UNITY Dx and Anterion. In eye care, a biometer is a device that uses laser technology to take highly precise measurements of the eye's internal structures. It is most frequently used to help determine the exact power of the intraocular lens (IOL) needed before cataract removal.

Eligibility

Sex
ALL
Min age
21 Years
Max age
—
Healthy volunteers
No
Inclusion Criteria: * Have healthy, clear corneas for the normal cohort; * Have documented keratoconus for the keratoconus cohort; * Have reported use of daily contact lens use for the contact lens cohort; * Have documented dry eye, consisting of signs and symptoms for the dry eye cohort; * Has had previous keratorefractive surgery for the post-refractive surgery cohort; * Able to comprehend and sign the informed consent form. Exclusion Criteria: * Active ocular infection or inflammation; * Unable to fixate due to nystagmus or other eye movement abnormality (e.g., significant strabismus); * Any ocular disease and/or condition that, in the investigator's clinical judgment, may put the subject at significant risk, may compromise study result or may interfere significantly with the subject's participation in the study.

Primary outcome measure(s)

  • Regression-Based Axial Length (R-AL) — Day 1
    Regression-based Axial Length (R-AL) is the distance from the anterior surface of the cornea to the retina at the back of the eye, measured along the visual axis. R-AL will be measured by the device and reported in microns.

Trial sites (1)

FacilityCityRegionStatus
The Eye Institute of Utah Salt Lake City Utah Recruiting

More Alcon Research trials in the USA

Capella Scientia Development Study Recruiting
UNITY DX Cornea Study Recruiting
Clareon TruPlus Study Recruiting
Efficacy and Safety of FID 123472 Ophthalmic Solution for Ocular Redness in Adults Recruiting
An Investigation of FID 123472 Ophthalmic Solution to Vehicle for the Reduction of Ocular Redness in Adults Recruiting
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT07782619 on ClinicalTrials.gov ↗ ← All trials in the USA